3ig6
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
{{Seed}} | {{Seed}} | ||
- | [[Image:3ig6. | + | [[Image:3ig6.png|left|200px]] |
<!-- | <!-- | ||
Line 23: | Line 23: | ||
==About this Structure== | ==About this Structure== | ||
- | 3IG6 is a 4 chains structure | + | 3IG6 is a 4 chains structure with sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3IG6 OCA]. |
==Reference== | ==Reference== | ||
Line 51: | Line 51: | ||
[[Category: Zymogen]] | [[Category: Zymogen]] | ||
- | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Jan 28 15:04:05 2010'' |
Revision as of 13:04, 28 January 2010
Contents |
Low molecular weigth human Urokinase type Plasminogen activator 2-[6-(3'-Aminomethyl-biphenyl-3-yloxy)-4-(3-dimethylamino-pyrrolidin-1-yl)-3,5-difluoro-pyridin-2-yloxy]-4-dimethylamino-benzoic acid complex
Template:ABSTRACT PUBMED 19703768
Disease
Known disease associated with this structure: Alzheimer disease, late-onset, susceptibility to OMIM:[191840]
About this Structure
3IG6 is a 4 chains structure with sequences from Homo sapiens. Full crystallographic information is available from OCA.
Reference
- West CW, Adler M, Arnaiz D, Chen D, Chu K, Gualtieri G, Ho E, Huwe C, Light D, Phillips G, Pulk R, Sukovich D, Whitlow M, Yuan S, Bryant J. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5712-5. Epub 2009 Aug 7. PMID:19703768 doi:10.1016/j.bmcl.2009.08.008
Page seeded by OCA on Thu Jan 28 15:04:05 2010
Categories: Homo sapiens | U-plasminogen activator | Adler, M. | Whitlow, M. | Blood coagulation | Disulfide bond | Egf-like domain | Fibrinolysis | Glycoprotein | Hydrolase | Kringle | Pharmaceutical | Phosphoprotein | Plasminogen activation | Polymorphism | Protease | S1 site inhibitor | Secreted | Selective | Serine protease | Structure-based drug design | Urokinase | Zymogen